Bonds & Credit Rating
In June 2018 DSM presented its Strategy Update: Growth & Value - Purpose led, Performance driven. With this new strategy DSM will evolve further towards being a purpose-led, science-based company in Nutrition, Health and Sustainable Living. We have created a strong platform for growth, centered on developing innovative solutions addressing Nutrition & Health, Climate & Energy and Resources & Circularity. Increased customer centricity and large innovation projects will enable above-market growth, while we will remain focused on cost control and operational excellence, allowing us to accelerate profit and cash generation. Organic growth will be complemented by acquisitions predominantly in Nutrition.
Most of DSM's external funding needs are financed through long-term debt. Debt covenants are not included in the terms and conditions of outstanding bonds and financing arrangements. DSM aims to spread the maturity profile of outstanding bonds in order to have adequate financial flexibility.
DSM has a commercial paper program of €1,500 million that is available and a committed €1,000 million credit facility maturing in May 2023.
DSM's policy in the various sub-disciplines of the finance function is strongly oriented toward solidity, reliability and protection of cash flows. The finance function plays an important role in business steering.
Royal DSM aims to maintain a strong investment grade long-term credit rating for senior unsecured debt. To this purpose, regular review meetings between rating agencies and DSM senior management are arranged. The rating agencies Moody’s and Standard & Poors have awarded the following ratings for the company’s short-term debt and long-term debt:
|Rating Agency||Long/short term rating||Outlook||Last Update|
|Moody's||A3 / P-2||Stable||31 July 2018
|Standard & Poor's||A- / A-2||Stable||29 March 2018
The weighted average interest rate of the bonds (including derivatives) was 3.28% in 2017 (3.40% in 2016).
This website contains information and documents which are for information purposes only. They neither constitute an offer nor an invitation nor a recommendation to subscribe to or to purchase, to hold or sell securities, nor are the information or documents contained on this website meant to serve as a basis for any kind of obligation, contractual or otherwise.
Publication of prospectuses on this website is done in accordance with legal requirements in connection with the admission to trading of securities.
Distribution of information and documents contained on this website, esp. prospectuses, may be forbidden or limited by legislation of some jurisdictions.
Access is denied to persons to whom these restrictions in such jurisdictions apply. Each visitor to this website is required to inform himself accordingly and to comply with applicable restrictions. Koninklijke DSM N.V. is in no way liable for any such infringement.
THE INFORMATION AND DOCUMENTS CONTAINED ON THIS WEBSITE ARE NOT DIRECTED AT AND MAY NOT BE VIEWED BY OR DISTRIBUTED TO ANY PERSON RESIDENT IN THE UNITED STATES OF AMERICA.
By entering the following parts of this website you confirm that you are not a resident of the United States of America and that you will not distribute any of the information and documents contained thereon to any person resident in the United States of America.
You further acknowledge that the following information and documents neither constitute an offer nor an invitation nor a recommendation to subscribe to or to purchase, to hold or sell securities.